Pfizer Inc. (PFE)
NYSE: PFEHealthcareDrug Manufacturers - GeneralUSD
At close: Oct 7, 4:02 PM ET · Delayed 15 min
After hours: 28.00 0.00%
PFE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $159.59B
- P/E (TTM)
- 36.84
- Forward P/E
- 9.67
- EPS (TTM)
- $0.76
- Dividend yield
- 6.14% ($1.72)
- Ex-dividend date
- Jul 24, 2026
- 52-week range
- 23.62 – 29.21
- Day range
- 27.55 – 28.17
- Volume / Avg
- 30.94M / 36.05M
- Beta
- —
- Shares outstanding
- 5.70B
- Next earnings
- Nov 3, 2026
52-week range
PFE stock today
On Oct 7, PFE ended the session at $28.00, adding $0.50 (1.82%), versus the S&P 500's 0.22% decline. Shares are 4.1% below their 52-week high of $29.21, set on Sep 3, 2026 and 18.5% above the 52-week low of $23.62, in the middle of the past year's range. PFE is up 12.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 6.6%.
At 36.8x trailing earnings, Pfizer trades above the peer-group median of 21.2x. Its forward P/E of 9.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Pfizer's next earnings report is expected on Nov 3, 2026. Pfizer pays an annual dividend of $1.72 per share, a 6.14% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Pfizer
Company profilePfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Dr. Albert Bourla D.V.M., Ph.D.
- Headquarters
- New York, NY
- Employees
- 75,000
- Website
- pfizer.com
Financial highlights
Full financialsIn fiscal 2025, Pfizer generated $62.58 billion in revenue, down 1.6% from fiscal 2024, its first annual decline since 2023. Net income was $7.77 billion (-3.2% year over year), for a net margin of 12.4% versus a median of 22.0% in the prior 5 years. Gross margin was 74.3% (up from 71.9%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B |
| Growth | -1.65% | +6.84% | -41.14% | +24.46% | +95.16% |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B |
| EPS (diluted) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$28.91+3.25%
- Strong buy 2
- Buy 8
- Hold 16
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.77
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-0.04 vs —
Dividends
Dividend history- Annual dividend
- $1.72
- Dividend yield
- 6.14%
- Last payment
- $0.43
- Ex-dividend date
- Jul 24, 2026
PFE news
All PFE news- Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancerSeeking Alpha
- Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy.NasdaqPFE, JPM, EPD
- 3 of the Best Dividend Stocks to Buy in October 2026NasdaqPFE, XOM, O
- Daily Dividend Report: PFE,WS,LW,MMSNasdaqPFE, WS, LW, MMS
- Pfizer Declares $0.43 Fourth-Quarter Dividend For ShareholdersNasdaq
- PFE vs. JNJ: Which Stock Is the Better Value Option?NasdaqPFE, JNJ
- AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCLNasdaqABBV, GMAB, PFE, FRO
- Are Investors Undervaluing Pfizer (PFE) Right Now?Nasdaq
Pfizer peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs PFE |
| GILDGilead Sciences Inc. | 146.85 | +1.82% | $182.09B | vs PFE |
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs PFE |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs PFE |
| GSKGSK plc ADR | 47.02 | +0.90% | $94.21B | vs PFE |
| AMGNAmgen Inc. | 413.08 | +2.60% | $223.32B | vs PFE |
| AZNAstraZeneca PLC | 160.12 | +0.95% | $248.33B | vs PFE |
| NVSNovartis AG | 143.28 | +1.77% | $272.33B | vs PFE |
Indexes, lists and sector
Index membership
Appears in lists
Pfizer stock FAQ
What is Pfizer's stock price today?
PFE last traded at $28.00 as of Oct 7, 4:02 PM EDT, up 1.82% on the day. Prices are delayed at least 15 minutes.
Does Pfizer pay a dividend?
Yes. Pfizer pays $1.72 per share annually, a 6.14% yield. The most recent dividend of $0.43 had an ex-dividend date of Jul 24, 2026.
When is Pfizer's next earnings date?
Pfizer is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.77.
What is PFE's P/E ratio?
PFE trades at a trailing P/E ratio of 36.84 and a forward P/E of 9.67, compared with a median of 21.2 for its closest peers.
Is Pfizer in the S&P 500?
Yes. Pfizer (PFE) is a constituent of the S&P 500 index.
Who is Pfizer's CEO?
Dr. Albert Bourla D.V.M., Ph.D. is the chief executive officer of Pfizer Inc., which has about 75,000 employees.
Has PFE ever split its stock?
Yes. The most recent PFE stock split was a 1054-for-1000 split on Nov 17, 2020, one of 6 splits on record.